Idbiologics
IDBiologics: Pioneering infectious disease treatment through rapid discovery and optimization of human monoclonal antibodies.
Founded
2017IDBiologics: Pioneering infectious disease treatment through rapid discovery and optimization of human monoclonal antibodies.
IDBiologics, founded in 2017, is dedicated to discovering and developing human monoclonal antibodies (mAbs) for the prevention, treatment, and cure of infectious diseases. Originating from the laboratory of Professor James Crowe at Vanderbilt University Medical Center, the company employs a cutting-edge fully human mAb platform that facilitates the rapid discovery and optimization of potent therapeutic molecules. Their market focus includes addressing a wide range of infectious diseases with their lead candidate molecules advancing through development stages.
Notable figures associated with IDBiologics include Professor James Crowe, whose pioneering work at Vanderbilt University laid the foundation for the company's innovative platform. The company has attracted significant attention and investment due to its unique approach and potential impact on global health. Key achievements include the successful isolation of broad and potent antibodies targeting diverse infectious agents. IDBiologics' efforts have the potential to revolutionize infectious disease treatment, offering new hope for rapid and effective therapeutic solutions.
Companies similar to Idbiologics include BioClonetics Immunotherapeutics, ImmuneID, Adimab and AbCellera Biologics.
Idbiologics was founded in 2017.
Idbiologics' headquarters is located in Nashville, TN, US.
Idbiologics' most recent funding round was for $500k (USD) in May 2023.
As of May 23, 2023, Idbiologics has raised a total of $4.8M (USD).
Idbiologics has 7 employees as of Feb 5, 2024.
adimab.com
